To the Editor: Approximately 35% of patients with stroke suffer symptoms of anxiety1 and about 17%–18% severe enough to have a DSM-IV-TR diagnosis of an anxiety disorder.2 Poststroke anxiety can lead to significant distress impairment on the subject’s daily functioning, interpersonal relationships and quality of life. There are very few studies on the treatment of poststroke anxiety. In a comparison study of acupuncture versus alprozolam, Wu and Liu (2008)3 found acupuncture to be safe and tolerable with improvement in anxiety but no different than alprazolam with regards to effectiveness. There are no other pharmacological studies on the treatment of poststroke anxiety. Since serotonin-selective reuptake inhibitors (SSRIs) are indicated for several anxiety disorders, we conducted a 16-week pilot study to assess the safety and tolerability of sertraline for the treatment of poststroke anxiety. We chose sertraline because it is well tolerated in the treatment of poststroke depression4,5 and has minimal drug-drug interactions particularly with warfarin anticoagulation therapy6 which is frequently used for secondary prevention of recurrent stroke.